Aravive Stock Forecast, Price & News

-0.02 (-0.39 %)
(As of 04/20/2021 12:00 AM ET)
Today's Range
Now: $5.17
50-Day Range
MA: $6.62
52-Week Range
Now: $5.17
Volume124,018 shs
Average Volume213,050 shs
Market Capitalization$101.64 million
P/E RatioN/A
Dividend YieldN/A
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Aravive logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARAV
Year FoundedN/A



Sales & Book Value

Annual Sales$4.75 million
Book Value$4.71 per share


Net Income$-18,220,000.00


Market Cap$101.64 million
Next Earnings Date5/5/2021 (Estimated)


Form 8-K Aravive, Inc. For: Mar 02 -
March 2, 2021 |
See More Headlines


Overall MarketRank

1.48 out of 5 stars

Medical Sector

565th out of 2,018 stocks

Pharmaceutical Preparations Industry

269th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
-0.02 (-0.39 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aravive (NASDAQ:ARAV) Frequently Asked Questions

Is Aravive a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive
or view top-rated stocks.

What stocks does MarketBeat like better than Aravive?

Wall Street analysts have given Aravive a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aravive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Aravive

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) posted its earnings results on Monday, March, 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.27. The business had revenue of $5.69 million for the quarter.
View Aravive's earnings history

How has Aravive's stock price been impacted by Coronavirus?

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAV stock has increased by 3.6% and is now trading at $5.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARAV?

6 Wall Street analysts have issued 12-month target prices for Aravive's stock. Their forecasts range from $20.00 to $30.00. On average, they anticipate Aravive's share price to reach $25.20 in the next year. This suggests a possible upside of 387.4% from the stock's current price.
View analysts' price targets for Aravive
or view top-rated stocks among Wall Street analysts.

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Dr. Gail F. McIntyre, CEO & Director (Age 58, Pay $453.34k)
  • Mr. Vinay Shah, Chief Financial Officer (Age 59, Pay $463.51k)
  • Dr. Raymond Tabibiazar M.D., Advisor
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 56)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Dr. Randy L. Anderson, Sr. VP of Data Sciences
  • Dr. Reshma Rangwala M.D., Ph.D., Chief Medical Officer
  • Kenneth L. Guernsey, Sec.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $5.17.

How much money does Aravive make?

Aravive has a market capitalization of $101.64 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How many employees does Aravive have?

Aravive employs 16 workers across the globe.

What is Aravive's official website?

The official website for Aravive is

Where are Aravive's headquarters?

Aravive is headquartered at River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 4/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.